Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.60 |
| ▸ | EGFR | P00533 | 7/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.52 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.52 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | PAK4 | O96013 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353197 | 0.89 | EGFR (0.57) | AURKAEGFRRIPK1AURKBPIK3C3 | |
| SCHEMBL12430891 | 0.88 | EGFR (0.70) | AURKAEGFRAURKBPIK3C3TBK1 | |
| SCHEMBL18154790 | 0.87 | PIK3C3 (0.65) | AURKAEGFRRIPK1AURKBPIK3C3 | |
| SCHEMBL18154662 | 0.85 | EGFR (0.53) | AURKAEGFRAURKBPIK3C3TBK1 | |
| Hydrochloric Acid SCHEMBL28463160 | 0.81 | AURKA (0.55) | AURKARIPK1AURKBTBK1PLK4 | |
| SCHEMBL28610702 | 0.78 | AURKA (0.52) | AURKARIPK1AURKBTBK1PLK4 | |
| SCHEMBL15704984 | 0.77 | EGFR (0.50) | AURKAEGFRRIPK1AURKBPIK3C3 | |
| SCHEMBL15705010 | 0.77 | EGFR (0.50) | AURKAEGFRRIPK1AURKBPIK3C3 | |
| SCHEMBL15705035 | 0.77 | EGFR (0.48) | AURKAEGFRRIPK1AURKBPIK3C3 | |
| SCHEMBL22534378 | 0.75 | PLK4 (0.61) | AURKARIPK1AURKBPLK4PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | AURKA 71/4885EGFR 2234/4885RIPK1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.